Timothy Bailey, MD
Endocrinology, Diabetes & Metabolism · Escondido, CANPI 1194800052
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 35.4% of the total. Reporting peaked in 2019 at $87,587 and has fallen 60.4% since, to $34,681 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $820.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$91K
- Abbott$62K
- Medtronic$34K
- Roche Diabetes Care GmbH$19K
- Novo Nordisk$19K
- Cequr Corporation$15K
- plus $17K from 19 others
Across 1,357 payments — averaging $16,284 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$7.7M
- Senseonics, Incorporated$6.2M
- Medtronic$2.9M
- Eli Lilly$2.2M
- Abbott$660K
- Sanofi US Services Inc.$630K
- plus $1.9M from 10 others
What the payments were for
- Consulting fees$108,02542%
- Speaking & faculty fees$101,55739%
- Travel & lodging$35,94614%
- Food & beverage$10,0794%
- Education$140%
- Charitable contribution$1,9211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 43 | $91,182 |
| Abbott | 110 | $62,242 |
| Medtronic(2 entities) | 57 | $34,233 |
| Roche Diabetes Care GmbH | 6 | $19,018 |
| Novo Nordisk | 20 | $18,837 |
| Cequr Corporation | 3 | $14,607 |
| Mannkind Corporation | 8 | $6,547 |
| Senseonics, Incorporated | 7 | $5,372 |
| F. Hoffmann-la Roche AG | 2 | $3,225 |
| AstraZeneca | 17 | $819 |
| Bigfoot Biomedical Inc | 8 | $697 |
| Insulet Corporation | 6 | $193 |
| Dexcom, Inc. | 3 | $92 |
| Lilly USA, LLC | 6 | $89 |
| Bayer | 2 | $62 |
| Roche Diagnostics Corporation | 1 | $60 |
| Ascendis Pharma Endocrinology Inc | 2 | $58 |
| Amgen(2 entities) | 3 | $58 |
| Ascensia Diabetes Care US Inc. | 2 | $37 |
| Madrigal Pharmaceuticals | 2 | $33 |
| BETA Bionics, Inc. | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $11 |
| Travere Therapeutics, Inc. | 2 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$86,528
- FREESTYLE LIBRE 3$21,001
- Accu-Chek Inform II Instrument with RF card$18,998
- FreeStyle Libre Pro$18,908
- FreeStyle Libre$16,197
- CeQur Simplicity$14,607
- AFREZZA$6,531
- Eversense$5,250
- Minimed 770G System$4,200
- Afinion 2$3,150
- MINIMED 770G$2,830
- Minimed 670G System$2,800
- Tresiba$2,062
- LANTUS$1,500
- SAR439954$1,346
- SOTAGLIFLOZIN$1,154
- MINIMED 780G$799
- UNITY DIABETES MANAGEMENT SYSTEM$562
- Ozempic$122
- Omnipod$100
How this compares
$257,541 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Somatuline DepotLanreotide Acetate | 12 | $67,491 |
| TymlosAbaloparatide | 15 | $52,459 |
| OzempicSemaglutide | 23 | $47,602 |
| Teriparatide | 18 | $38,862 |
| JardianceEmpagliflozin | 21 | $33,796 |
| ProliaDenosumab | 16 | $26,502 |
| FarxigaDapagliflozin Propanediol | 22 | $19,834 |
| JanuviaSitagliptin Phosphate | 11 | $6,577 |
| SynthroidLevothyroxine Sodium | 62 | $6,175 |
| Levothyroxine Sodium | 335 | $4,128 |
| Testosterone | 36 | $4,084 |
| Armour ThyroidThyroid,pork | 27 | $2,680 |
| Hydrocortisone | 35 | $2,580 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,581 |
| Testosterone Cypionate | 23 | $1,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $18,837 | $47,60223 claims |
| AmgenProlia | $58 | $26,50216 claims |
| AstraZenecaFarxiga | $819 | $19,83422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Escondido
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.